摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-羟基-2-甲氧基-苯甲酰胺 | 771-28-8

中文名称
N-羟基-2-甲氧基-苯甲酰胺
中文别名
2-甲氧基苯甲酰胺肟
英文名称
N'-hydroxy-2-methoxybenzimidamide
英文别名
2-methoxybenzamidoxime;N'-hydroxy-2-methoxybenzenecarboximidamide
N-羟基-2-甲氧基-苯甲酰胺化学式
CAS
771-28-8
化学式
C8H10N2O2
mdl
MFCD06366748
分子量
166.18
InChiKey
NFAJEYBUPFIZNQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    115-116 °C
  • 沸点:
    298.7±42.0 °C(Predicted)
  • 密度:
    1.21±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.1
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.125
  • 拓扑面积:
    67.8
  • 氢给体数:
    2
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2925290090

SDS

SDS:ff95f5667b926dc1502cb06b323e83ea
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    N-羟基-2-甲氧基-苯甲酰胺 在 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 0.08h, 生成 Tert-butyl 4-[3-(2-methoxyphenyl)-1,2,4-oxadiazol-5-yl]piperidine-1-carboxylate
    参考文献:
    名称:
    Ethionamide Boosters. 2. Combining Bioisosteric Replacement and Structure-Based Drug Design To Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors
    摘要:
    Mycobacterial transcriptional repressor EthR controls the expression of EthA, the bacterial monooxygenase activating ethionamide, and is thus largely responsible for the low sensitivity of the human pathogen Mycobacterium tuberculosis to this antibiotic. We recently reported structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors leading to the discovery of potent ethionamide boosters. Despite high metabolic stability, pharmacokinetic evaluation revealed poor mice exposure; therefore, a second phase of optimization was required. Herein a structure-property relationship study is reported according to the replacement of the two aromatic heterocycles: 2-thienyl and 1,2,4-oxadiazolyl moieties. This work was done using a combination of structure-based drug design and in vitro/ex vivo evaluations of ethionamide boosters on the targeted protein EthR and on the human pathogen Mycobacterium tuberculosis. Thanks to this process, we identified compound 42 (BDM41906), which displays improved efficacy in addition to high exposure to mice after oral administration.
    DOI:
    10.1021/jm200825u
  • 作为产物:
    描述:
    参考文献:
    名称:
    Miller, Chemische Berichte, 1889, vol. 22, p. 2801
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • [EN] NEW THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX DÉRIVÉS DE THIÉNOPYRIMIDINE, PROCÉDÉ POUR LEUR PRÉPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
    申请人:SERVIER LAB
    公开号:WO2015097123A1
    公开(公告)日:2015-07-02
    Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R12, X, A and n are as defined in the description.
    式(I)的化合物:其中R1、R2、R3、R4、R5、R6、R7、R12、X、A和n的定义如描述中所述。
  • 1,2,3-Triazoles as Amide Bioisosteres: Discovery of a New Class of Potent HIV-1 Vif Antagonists
    作者:Idrees Mohammed、Indrasena Reddy Kummetha、Gatikrushna Singh、Natalia Sharova、Gianluigi Lichinchi、Jason Dang、Mario Stevenson、Tariq M. Rana
    DOI:10.1021/acs.jmedchem.6b00247
    日期:2016.8.25
    A3G-dependent Vif degradation. Replacement of amide functionality in RN-18 (IC50 = 6 μM) by isosteric heterocycles resulted in the discovery of a 1,2,3-trizole, 1d (IC50 = 1.2 μM). We identified several potent HIV-1 inhibitors from a 1d based library including 5ax (IC50 = 0.01 μM), 5bx (0.2 μM), 2ey (0.4 μM), 5ey (0.6 μM), and 6bx (0.2 μM).
    Vif拮抗剂是基于RN-18的病毒感染因子(Vif),可通过拯救APOBEC3G(A3G)表达并增强A3G依赖性Vif降解来降低病毒感染性。用等位杂环取代RN-18中的酰胺官能团(IC 50 = 6μM)导致发现1,2,3-三唑,1d(IC 50 = 1.2μM)。我们从基于1d的文库中鉴定了几种有效的HIV-1抑制剂,包括5ax(IC 50 = 0.01μM),5bx(0.2μM),2ey(0.4μM),5ey(0.6μM)和6bx(0.2μM)。
  • A convenient and mild method for 1,2,4-oxadiazole preparation: cyclodehydration of O -acylamidoximes in the superbase system MOH/DMSO
    作者:Sergey Baykov、Tatyana Sharonova、Angelina Osipyan、Sergey Rozhkov、Anton Shetnev、Alexey Smirnov
    DOI:10.1016/j.tetlet.2016.05.071
    日期:2016.6
    Herein, we reported a general, convenient, and efficient synthesis of 3,5-disubstituted-1,2,4-oxadiazoles via cyclodehydration of O-acylamidoximes in the superbase system MOH/DMSO (M = Li, Na, K). Excellent isolated yields (up to 98%) were attained within short reaction times (10–20 min). In addition, mild reaction conditions and a simple work-up procedure allow the synthesis of a wide range of heat-labile
    在本文中,我们报道了在超碱系统MOH / DMSO(M = Li,Na,K)中通过O-酰基酰胺基肟的环脱水作用,一种一般,便捷,有效的合成3,5-二取代-1,2,4-恶二唑的方法。在较短的反应时间内(10-20分钟)即可获得出色的分离产率(高达98%)。此外,温和的反应条件和简单的后处理程序可以合成多种热不稳定的含1,2,4-恶二唑的物质。
  • Structure–activity relationships of acyloxyamidine cytomegalovirus DNA polymerase inhibitors
    作者:John A. Tucker、Terrance L. Clayton、Connie G. Chidester、Martin W. Schulz、Leigh E. Harrington、Steven J. Conrad、Yoshihiko Yagi、Nancee L. Oien、David Yurek、Ming-Shang Kuo
    DOI:10.1016/s0968-0896(99)00319-3
    日期:2000.3
    initio molecular orbital calculations combined with qualitative estimates of steric interaction energies suggest that the lowest energy conformations of the acyloxyamidine linker are characterized by an extended planar CAr-C=N-O-C arrangement and either a syn-periplanar or anti-periplanar N-O-C-C(Ar') arrangement. Only the anti-periplanar conformation was observed in the crystal structures of three
    本文描述了新型的巨细胞病毒DNA聚合酶抑制剂的结构活性关系,该抑制剂具有两个通过酰氧基oxy连接子连接的芳基。对其中末端基团不同的一系列类似物的研究表明,在先导化合物的2,4-二氯苯基周围有非常窄的SAR,但苯并噻唑环的各种替代物均具有活性。其中最引人注目的是化合物78的异恶唑环,与先导化合物相比,其效价提高了30倍。我们还描述了10个类似物的设计,合成和评估,其中酰氧基am连接基被等位基团修饰或替代。结构-活性关系研究确定了接头-NH2基团是关键的药效学元素。从头算分子轨道计算与对空间相互作用能的定性估计相结合,表明酰氧基am连接子的最低能构象具有扩展的平面CAr-C = NOC排列以及同平面或反平面NOCC(Ar')安排。在三个酰氧基am的晶体结构中仅观察到反平面构象。在这些研究的基础上设计的最有效的连接基修饰化合物是氨基甲酸20 20,在巨细胞病毒DNA聚合酶抑制试验中,氨基甲酸am的含量约为对照酰氧基am
  • [EN] BROAD SPECTRUM ANTIVIRAL COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS ANTIVIRAUX À SPECTRE LARGE ET LEURS UTILISATIONS
    申请人:UNIV CALIFORNIA
    公开号:WO2017040693A1
    公开(公告)日:2017-03-09
    Disclosed herein, inter alia, are agents having antiviral activity and methods of use thereof.
    在此披露的内容包括具有抗病毒活性的药剂和使用方法。
查看更多